Table 3 Long-term efficacy results for patients with investigator-defined total spinal ankylosis or Stage V radiographic criteria*

Response variable	Investigator-defined TSA		Stage V TSA
	Total duration of adalimumab exposure		Total duration of adalimumab exposure
	1 year (n = 11), (%)	2 years (n = 8), (%)	1 year (n = 8), (%)	2 years (n = 5), (%)
ASAS20	72.7	75.0	62.5	60.0
ASAS40	36.4	62.5	37.5	40.0
ASAS 5/6	54.5	37.5	37.5	20.0
ASAS partial remission	9.1	0	12.5	0
BASDAI 50	45.5	62.5	50.0	60.0

ASAS, ASsessment in Ankylosing Spondylitis International Working Group criteria for improvement; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; TSA, total spinal ankylosis.
*All data are based on observed efficacy analyses.